Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Diabetes Reports
Erschienen in: Current Diabetes Reports 9/2021

01.09.2021 | Microvascular Complications—Retinopathy (R Channa, Section Editor)

Laser Therapy in the Treatment of Diabetic Retinopathy and Diabetic Macular Edema

verfasst von: Lesley A. Everett, Yannis M. Paulus

Erschienen in: Current Diabetes Reports | Ausgabe 9/2021

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

This review highlights indications and evidence on laser therapy in the management of diabetic retinopathy and diabetic macular edema. Particular focus is placed upon the benefits and limitations of conventional laser photocoagulation versus more modern laser photocoagulation techniques, as well as the role of laser photocoagulation in treatment of diabetic retinopathy and diabetic macular edema with the frequent utilization of pharmacologic, including anti-vascular endothelial growth factor (VEGF), therapy.

Recent Findings

Laser photocoagulation remains the gold-standard therapy for the effective, definitive treatment of PDR, and also is highly effective in the management of DME. However, numerous recent studies have demonstrated the clinical efficacy and improved functional and anatomic outcomes of combination therapy with pharmacologic treatment.

Summary

Continuing innovations in laser technology and improved understanding of laser-retinal interactions and pathophysiology demonstrate that laser therapy will continue to play a critical role in the treatment of diabetic retinopathy and diabetic macular edema for many years to come.
Literatur
1.
CR M. Lasers in opthalmology: past, present and future. J Mod Opt. 2003;50(15-17):2351–60.
2.
CDC. Diabetic Retinopathy 2020 [3/21/21]. Available from: https://​www.​cdc.​gov/​visionhealth/​pdf/​factsheet.​pdf.​
3.
4.
Blumenkranz MS. The evolution of laser therapy in ophthalmology: a perspective on the interactions between photons, patients, physicians, and physicists: the LXX Edward Jackson Memorial Lecture. Am J Ophthalmol. 2014;158(1):12–25 e1.PubMedCrossRef
5.
6.
7.
Xie X, Liu Q, Paulus YM. Novel retinal laser therapies. Int J Ophthalmic Res. 2018;4(1):272–9.
8.
WB B. Laser oscillation in singly ionized argon in the visible spectrum. Appl Phys Lett. 1964;4(7):128–30.CrossRef
9.
Birngruber R, Hillenkamp F, Gabel VP. Theoretical investigations of laser thermal retinal injury. Health Phys. 1985;48(6):781–96.PubMedCrossRef
10.
Lock JH, Fong KC. Retinal laser photocoagulation. Med J Malaysia. 2010;65(1):88–94 quiz 5.PubMed
11.
Paulus YM, Jain A, Gariano RF, Stanzel BV, Marmor M, Blumenkranz MS, et al. Healing of retinal photocoagulation lesions. Invest Ophthalmol Vis Sci. 2008;49(12):5540–5.PubMedCrossRef
12.
Wolbarsht ML, Landers MB 3rd. The rationale of photocoagulation therapy for proliferative diabetic retinopathy: a review and a model. Ophthalmic Surg. 1980;11(4):235–45.PubMed
13.
Stefansson E. The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol Scand. 2001;79(5):435–40.PubMedCrossRef
14.
Ascaso FJ, Huerva V, Grzybowski A. The role of inflammation in the pathogenesis of macular edema secondary to retinal vascular diseases. Mediat Inflamm. 2014;2014:432685.CrossRef
15.
Ogata N, Ando A, Uyama M, Matsumura M. Expression of cytokines and transcription factors in photocoagulated human retinal pigment epithelial cells. Graefes Arch Clin Exp Ophthalmol. 2001;239(2):87–95.PubMedCrossRef
16.
Arnarsson A, Stefansson E. Laser treatment and the mechanism of edema reduction in branch retinal vein occlusion. Invest Ophthalmol Vis Sci. 2000;41(3):877–9.PubMed
17.
Wilson DJ, Finkelstein D, Quigley HA, Green WR. Macular grid photocoagulation. An experimental study on the primate retina. Arch Ophthalmol. 1988;106(1):100–5.PubMedCrossRef
18.
Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema. Long-term visual results. Ophthalmology. 1991;98(10):1594–602.PubMedCrossRef
19.
Olk RJ. Modified grid argon (blue-green) laser photocoagulation for diffuse diabetic macular edema. Ophthalmology. 1986;93(7):938–50.PubMedCrossRef
20.
Olk RJ. Argon green (514 nm) versus krypton red (647 nm) modified grid laser photocoagulation for diffuse diabetic macular edema. Ophthalmology. 1990;97(9):1101–12 discussion 12-3.PubMedCrossRef
21.
Striph GG, Hart WM Jr, Olk RJ. Modified grid laser photocoagulation for diabetic macular edema. The effect on the central visual field. Ophthalmology. 1988;95(12):1673–9.PubMedCrossRef
22.
Little HL, Zweng HC, Peabody RR. Argon laser slit-lamp retinal photocoagulation. Trans Am Acad Ophthalmol Otolaryngol. 1970;74(1):85–97.PubMed
23.
Law NM, Fan RF. Clinical experience with the laser indirect ophthalmoscope. Ann Acad Med Singap. 1991;20(6):750–4.PubMed
24.
25.
Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1987;94(7):761–74.
26.
Prskavec FH, Fulmek R, Klemen C, Stelzer N. Changes in the visual field and dark adaptation following panretinal photocoagulation in diabetic retinopathy. Klin Monatsbl Augenheilkd. 1986;189(5):385–7.PubMedCrossRef
27.
Russell PW, Sekuler R, Fetkenhour C. Visual function after pan-retinal photocoagulation: a survey. Diabetes Care. 1985;8(1):57–63.PubMedCrossRef
28.
Blondeau P, Pavan PR, Phelps CD. Acute pressure elevation following panretinal photocoagulation. Arch Ophthalmol. 1981;99(7):1239–41.PubMedCrossRef
29.
Irvine WD, Smiddy WE, Nicholson DH. Corneal and iris burns with the laser indirect ophthalmoscope. Am J Ophthalmol. 1990;110(3):311–3.PubMedCrossRef
30.
Lobes LA Jr, Bourgon P. Pupillary abnormalities induced by argon laser photocoagulation. Ophthalmology. 1985;92(2):234–6.PubMedCrossRef
31.
Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. The Diabetic Retinopathy Study Research Group. Ophthalmology. 1981;88(7):583–600.
32.
Four risk factors for severe visual loss in diabetic retinopathy. The third report from the Diabetic Retinopathy Study. The Diabetic Retinopathy Study Research Group. Arch Ophthalmol. 1979;97(4):654–5.CrossRef
33.
Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol. 1985;103(12):1796–806.CrossRef
34.
35.
Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991;98(5 Suppl):766–85.
36.
Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: Early Treatment Diabetic Retinopathy Study Report no. 3. The Early Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin. 1987;27(4):254–64.
37.
Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study Report no. 4. The Early Treatment Diabetic Retinopathy Study Research Group. Int Ophthalmol Clin. 1987;27(4):265–72.
38.
Roider J. Laser treatment of retinal diseases by subthreshold laser effects. Semin Ophthalmol. 1999;14(1):19–26.PubMedCrossRef
39.
Schatz H, Madeira D, McDonald HR, Johnson RN. Progressive enlargement of laser scars following grid laser photocoagulation for diffuse diabetic macular edema. Arch Ophthalmol. 1991;109(11):1549–51.PubMedCrossRef
40.
Friberg TR. Subthreshold (invisible) modified grid diode laser photocoagulation and diffuse diabetic macular edema (DDME). Ophthalmic Surg Lasers. 1999;30(9):705.PubMedCrossRef
41.
Writing Committee for the Diabetic Retinopathy Clinical Research N, Fong DS, Strauber SF, Aiello LP, Beck RW, Callanan DG, et al. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol. 2007;125(4):469–80.CrossRef
42.
Romero-Aroca P, Reyes-Torres J, Baget-Bernaldiz M, Blasco-Sune C. Laser treatment for diabetic macular edema in the 21st century. Curr Diabetes Rev. 2014;10(2):100–12.PubMedPubMedCentralCrossRef
43.
Blumenkranz MS, Yellachich D, Andersen DE, Wiltberger MW, Mordaunt D, Marcellino GR, et al. Semiautomated patterned scanning laser for retinal photocoagulation. Retina. 2006;26(3):370–6.PubMedCrossRef
44.
Paulus YM, Kaur K, Egbert PR, Blumenkranz MS, Moshfeghi DM. Human histopathology of PASCAL laser burns. Eye (Lond). 2013;27(8):995–6.CrossRef
45.
Jain A, Blumenkranz MS, Paulus Y, Wiltberger MW, Andersen DE, Huie P, et al. Effect of pulse duration on size and character of the lesion in retinal photocoagulation. Arch Ophthalmol. 2008;126(1):78–85.PubMedCrossRef
46.
Sher A, Jones BW, Huie P, Paulus YM, Lavinsky D, Leung LS, et al. Restoration of retinal structure and function after selective photocoagulation. J Neurosci. 2013;33(16):6800–8.PubMedPubMedCentralCrossRef
47.
Muqit MM, Marcellino GR, Gray JC, McLauchlan R, Henson DB, Young LB, et al. Pain responses of Pascal 20 ms multi-spot and 100 ms single-spot panretinal photocoagulation: Manchester Pascal Study, MAPASS report 2. Br J Ophthalmol. 2010;94(11):1493–8.PubMedCrossRef
48.
Sramek C, Leung LS, Leng T, Brown J, Paulus YM, Schuele G, et al. Improving the therapeutic window of retinal photocoagulation by spatial and temporal modulation of the laser beam. J Biomed Opt. 2011;16(2):028004.PubMedCrossRef
49.
Sramek CK, Leung LS, Paulus YM, Palanker DV. Therapeutic window of retinal photocoagulation with green (532-nm) and yellow (577-nm) lasers. Ophthalmic Surg Lasers Imaging. 2012;43(4):341–7.PubMedCrossRef
50.
Nagpal M, Marlecha S, Nagpal K. Comparison of laser photocoagulation for diabetic retinopathy using 532-nm standard laser versus multispot pattern scan laser. Retina. 2010;30(3):452–8.PubMedCrossRef
51.
Chappelow AV, Tan K, Waheed NK, Kaiser PK. Panretinal photocoagulation for proliferative diabetic retinopathy: pattern scan laser versus argon laser. Am J Ophthalmol. 2012;153(1):137–42 e2.PubMedCrossRef
52.
Palanker D, Blumenkranz MS. Panretinal photocoagulation for proliferative diabetic retinopathy. Am J Ophthalmol. 2012;153(4):780–1 author reply 1-2.PubMedCrossRef
53.
Muqit MM, Gray JC, Marcellino GR, Henson DB, Young LB, Patton N, et al. Barely visible 10-millisecond pascal laser photocoagulation for diabetic macular edema: observations of clinical effect and burn localization. Am J Ophthalmol. 2010;149(6):979–86 e2.PubMedCrossRef
54.
Muqit MM, Sanghvi C, McLauchlan R, Delgado C, Young LB, Charles SJ, et al. Study of clinical applications and safety for Pascal(R) laser photocoagulation in retinal vascular disorders. Acta Ophthalmol. 2012;90(2):155–61.PubMedCrossRef
55.
Gabel V-P BR, Hillenkamp F. Visible and near infrared light absorption in pigment epithelium and choroid. XXIII Concilium Ophthalmologicum. 1978;450:658–62.
56.
Roider J, Brinkmann R, Wirbelauer C, Laqua H, Birngruber R. Subthreshold (retinal pigment epithelium) photocoagulation in macular diseases: a pilot study. Br J Ophthalmol. 2000;84(1):40–7.PubMedPubMedCentralCrossRef
57.
Paulus YM, Jain A, Nomoto H, Sramek C, Gariano RF, Andersen D, et al. Selective retinal therapy with microsecond exposures using a continuous line scanning laser. Retina. 2011;31(2):380–8.PubMedCrossRef
58.
Brinkmann R, Roider J, Birngruber R. Selective retina therapy (SRT): a review on methods, techniques, preclinical and first clinical results. Bull Soc Belge Ophtalmol. 2006;302:51–69.
59.
Roider J, Liew SH, Klatt C, Elsner H, Poerksen E, Hillenkamp J, et al. Selective retina therapy (SRT) for clinically significant diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2010;248(9):1263–72.PubMedCrossRef
60.
Brinkmann R, Schüle G, Joachimmeyer E, Roider J, Birngruber R, “Determination of absolute fundus temperatures during retinal laser photocoagulation and selective RPE treatment,” Invest. Ophthalmol. Visual Sci. (2001);42:696.
61.
Paulus YM. Short-pulse laser treatment: redefining retinal therapy. Retin Physician. 2010;2011:1–9.
62.
63.
Flaxel C, Bradle J, Acott T, Samples JR. Retinal pigment epithelium produces matrix metalloproteinases after laser treatment. Retina. 2007;27(5):629–34.PubMedCrossRef
64.
Hattenbach LO, Beck KF, Pfeilschifter J, Koch F, Ohrloff C, Schacke W. Pigment-epithelium-derived factor is upregulated in photocoagulated human retinal pigment epithelial cells. Ophthalmic Res. 2005;37(6):341–6.PubMedCrossRef
65.
Mainster MA. Decreasing retinal photocoagulation damage: principles and techniques. Semin Ophthalmol. 1999;14(4):200–9.PubMedCrossRef
66.
Sivaprasad S, Elagouz M, McHugh D, Shona O, Dorin G. Micropulsed diode laser therapy: evolution and clinical applications. Surv Ophthalmol. 2010;55(6):516–30.PubMedCrossRef
67.
68.
Su D, Hubschman JP. A review of subthreshold micropulse laser and recent advances in retinal laser technology. Ophthalmol Therapy. 2017;6(1):1–6.CrossRef
69.
Luttrull JK, Dorin G. Subthreshold diode micropulse laser photocoagulation (SDM) as invisible retinal phototherapy for diabetic macular edema: a review. Curr Diabetes Rev. 2012;8(4):274–84.PubMedPubMedCentralCrossRef
70.
Sivaprasad S, Sandhu R, Tandon A, Sayed-Ahmed K, McHugh DA. Subthreshold micropulse diode laser photocoagulation for clinically significant diabetic macular oedema: a three-year follow up. Clin Exp Ophthalmol. 2007;35(7):640–4.PubMedCrossRef
71.
Figueira J, Khan J, Nunes S, Sivaprasad S, Rosa A, de Abreu JF, et al. Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. Br J Ophthalmol. 2009;93(10):1341–4.PubMedCrossRef
72.
Lavinsky D, Cardillo JA, Melo LA Jr, Dare A, Farah ME, Belfort R Jr. Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema. Invest Ophthalmol Vis Sci. 2011;52(7):4314–23.PubMedCrossRef
73.
Lavinsky D, Sramek C, Wang J, Huie P, Dalal R, Mandel Y, et al. Subvisible retinal laser therapy: titration algorithm and tissue response. Retina. 2014;34(1):87–97.PubMedCrossRef
74.
Lai, K., et al. Subthreshold Pan-Retinal Photocoagulation Using Endpoint Management Algorithm for Severe Nonproliferative Diabetic Retinopathy: A Paired Controlled Pilot Prospective Study. Ophthalmic Res. 2021;64(4):648-655.
75.
Jung JJ, Gallego-Pinazo R, Lleo-Perez A, Huz JI, Barbazetto IA. NAVILAS laser system focal laser treatment for diabetic macular edema-one year results of a case series. Open Ophthalmol J. 2013;7:48–53.PubMedPubMedCentralCrossRef
76.
Kozak I, Oster SF, Cortes MA, Dowell D, Hartmann K, Kim JS, et al. Clinical evaluation and treatment accuracy in diabetic macular edema using navigated laser photocoagulator NAVILAS. Ophthalmology. 2011;118(6):1119–24.PubMedCrossRef
77.
Ober MD, Kernt M, Cortes MA, Kozak I. Time required for navigated macular laser photocoagulation treatment with the Navilas. Graefes Arch Clin Exp Ophthalmol. 2013;251(4):1049–53.PubMedCrossRef
78.
Kernt M, Cheuteu R, Vounotrypidis E, Haritoglou C, Kampik A, Ulbig MW, et al. Focal and panretinal photocoagulation with a navigated laser (NAVILAS(R)). Acta Ophthalmol. 2011;89(8):e662–4.PubMedCrossRef
79.
Hu Z, Zhang H, Mordovanakis A, Paulus YM, Liu Q, Wang X, et al. High-precision, non-invasive anti-microvascular approach via concurrent ultrasound and laser irradiation. Sci Rep. 2017;7:40243.PubMedPubMedCentralCrossRef
80.
Zhang H, Xie X, Li J, Qin Y, Zhang W, Cheng Q, et al. Removal of choroidal vasculature using concurrently applied ultrasound bursts and nanosecond laser pulses. Sci Rep. 2018;8(1):12848.PubMedPubMedCentralCrossRef
81.
Paulus YM, Qin Y, Yu Y, Fu J, Wang X, Yang X. Photo-mediated ultrasound therapy to treat retinal neovascularization. Annu Int Conf IEEE Eng Med Biol Soc. 2020;2020:5244–7.PubMed
82.
DRCR N. A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology Ophthalmology. 2008;115(9):1447–145010.
83.
Diabetic Retinopathy Clinical Research N, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114(10):1860–7.CrossRef
84.
Diabetic Retinopathy Clinical Research N, Elman MJ, Qin H, Aiello LP, Beck RW, Bressler NM, et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results. Ophthalmology. 2012;119(11):2312–8.CrossRef
85.
Diabetic Retinopathy Clinical Research N, Googe J, Brucker AJ, Bressler NM, Qin H, Aiello LP, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina. 2011;31(6):1009–27.CrossRef
86.
Writing Committee for the Diabetic Retinopathy Clinical Research N, Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, et al. Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA. 2015;314(20):2137–46.CrossRef
87.
Gross JG, Glassman AR, Liu D, Sun JK, Antoszyk AN, Baker CW, et al. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial. JAMA Ophthalmol. 2018;136(10):1138–48.PubMedPubMedCentralCrossRef
88.
Tao, Y., et al. Retrospective study of aflibercept in combination therapy for high-risk proliferative diabetic retinopathy and diabetic maculopathy. Int Ophthalmol. 2021 Jun;41(6):2157-2165.
89.
Altinel, MG., et al. Comparison of the efficacy and safety of anti-VEGF monotherapy versus anti-VEGF therapy combined with subthreshold micropulse laser therapy for diabetic macular edema. Lasers Med Sci. 2021 Sep;36(7):1545-1553.
90.
Gawecki M. Subthreshold diode micropulse laser combined with intravitreal therapy for macular edema-a systematized review and critical approach. J Clin Med. 2021;10(7).
91.
Nomoto H, Lavinsky D, Paulus YM, Leung LS, Dalal R, Blumenkranz MS, et al. Effect of intravitreal triamcinolone acetonide on healing of retinal photocoagulation lesions. Retina. 2013;33(1):63–70.PubMedCrossRef
92.
Dot C, Behar-Cohen F, BenEzra D, Doat M, Jonet L, May F, et al. Influence of triamcinolone intravitreal injection on retinochoroidal healing processes. Exp Eye Res. 2007;84(6):1081–9.PubMedCrossRef
93.
Lindeke-Myers, A., et al. Patient Perceptions of SARS-CoV-2 Exposure Risk and Association with Continuity of Ophthalmic Care. JAMA Ophthalmol. 2021 May 1;139(5):508-515.
94.
Corazza P, D'Alterio FM, Younis S. Proposed algorithm during COVID-19 pandemic for patient management in medical retina clinic. Int J Retina Vitreous. 2020;6:20.PubMedPubMedCentralCrossRef
95.
Yang KB, Feng H, Zhang H. Effects of the COVID-19 pandemic on anti-vascular endothelial growth factor treatment in China. Front Med (Lausanne). 2020;(7):576275.
96.
97.
Moussa, M., et al. Intravitreal injections of anti-VEGF agents during COVID-19 pandemic: clinical audit from Tanta University Hospital. Int Ophthalmol. 2021 Apr;41(4):1437-1443.
98.
Obeid A, Su D, Patel SN, Uhr JH, Borkar D, Gao X, et al. Outcomes of eyes lost to follow-up with proliferative diabetic retinopathy that received panretinal photocoagulation versus intravitreal anti-vascular endothelial growth factor. Ophthalmology. 2019;126(3):407–13.PubMedCrossRef
99.
Wubben TJ, Johnson MW, Anti VTISG. Anti-vascular endothelial growth factor therapy for diabetic retinopathy: consequences of inadvertent treatment interruptions. Am J Ophthalmol. 2019;204:13–8.PubMedCrossRef
100.
Metadaten
Titel
Laser Therapy in the Treatment of Diabetic Retinopathy and Diabetic Macular Edema
verfasst von
Lesley A. Everett
Yannis M. Paulus
Publikationsdatum
01.09.2021
Verlag
Springer US
Erschienen in
Current Diabetes Reports / Ausgabe 9/2021
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-021-01403-6

Weitere Artikel der Ausgabe 9/2021

Current Diabetes Reports 9/2021 Zur Ausgabe

Microvascular Complications—Retinopathy (R Channa, Section Editor)

Management of Complications and Vision Loss from Proliferative Diabetic Retinopathy

Microvascular Complications—Retinopathy (R Channa, Section Editor)

Toward a New Staging System for Diabetic Retinopathy Using Wide Field Swept-Source Optical Coherence Tomography Angiography

Hospital Management of Diabetes (A Wallia and J Seley, Section Editors)

Predicting and Preventing Acute Care Re-Utilization by Patients with Diabetes

Lifestyle Management to Reduce Diabetes/Cardiovascular Risk (B Conway and H Keenan, Section Editors)

Efficacy of Ketogenic Diets on Type 2 Diabetes: a Systematic Review

Microvascular Complications—Neuropathy (R Pop-Busui, Section Editor)

Molecular Aspects in the Potential of Vitamins and Supplements for Treating Diabetic Neuropathy

Microvascular Complications—Retinopathy (R Channa, Section Editor)

The Role of Ultra-Widefield Fundus Imaging and Fluorescein Angiography in Diagnosis and Treatment of Diabetic Retinopathy

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise